Covid-19 roundup: CanSi­no sub­mits vac­cine to Chi­nese reg­u­la­tors; As­traZeneca says an­ti­bod­ies show ear­ly ef­fi­ca­cy against new vari­ants — re­port

CanSi­no says their sin­gle-dose Covid-19 vac­cine is 65.28% ef­fec­tive at pre­vent­ing symp­to­matic Covid-19 cas­es, and they’ve of­fi­cial­ly filed for au­tho­riza­tion with Chi­na’s Na­tion­al Med­ical Prod­ucts Ad­min­is­tra­tion.

The vac­cine was 90.07% ef­fec­tive at pre­vent­ing se­vere dis­ease 28 days af­ter the sin­gle dose, ac­cord­ing to a state­ment re­port­ed by lo­cal me­dia. Ef­fi­ca­cy rates were slight­ly high­er 14 days af­ter the sin­gle dose, at 68.83% for symp­to­matic dis­ease and  95.47% for se­vere dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.